EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model

Marion Giry, Charles Baulier, Fabien Lamoureux, Manuel Etienne iD, Nicolas Nessi, François Gravey iD, Kévin Alexandre iD

Microbiology Spectrum · 03.11.2026 · 14 (11)

DOI: 10.1128/spectrum.01457-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Marion Giry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Intensive Care, Univ Rouen Normandie, Univ de Caen Normandie, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Rouen, France. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, beta-Lactamases, Escherichia coli Infections. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of piperacillin-tazobactam (TZP) in the treatment of severe extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) infections is controversial. Two features may explain treatment failures: the inoculum effect and suboptimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment, particularly in critically ill patients. To study the combined impact of the inoculum effect and a PK/PD optimization on the in vitro efficacy of TZP against ESBL-EC infections. Five-day hollow-fiber infection model simulating TZP pharmacokinetics in critically ill patients was performed: two TZP infusion regimens (4/0.5 g q6h over 30 min, and 16/2 g q24h continuous infusion), three ESBL-EC clinical strains: 1146 ( bla CTX-M-15 , MIC = 2 mg/L), 3383 ( bla CTX-M-15 + bla TEM-1 , MIC = 4 mg/L), and 2262 ( bla CTX-M-15 + bla OXA-1 , MIC = 8 mg/L), and two initial inocula (5 and 7 log 10 CFU/mL). Intermittent infusion was associated with systematic bacterial regrowth within 24 h, consistent with failure to reach the 100%fT >4× MIC threshold. Continuous infusion resulted in undetectable bacterial count for the strains 3383 (MIC = 4 mg/L, low inoculum) and 1146 (MIC = 2 mg/L, low and high inocula). For strain 3383 , the inoculum effect was demonstrated by total bacterial killing in continuous infusion with low inoculum, whereas early regrowth (>10 log 10 CFU/mL) with resistance emergence (MIC > 256 mg/L) was observed with high inoculum. Strain 2262 (MIC = 8 mg/L) exhibited systematic treatment failure regardless of infusion mode or inoculum size. Continuous infusion of TZP may be considered as a carbapenem-sparing agent in ESBL-EC infection with a TZP MIC ≤ 2 mg/L regardless of inoculum, or a TZP MIC of 4 mg/L at low inoculum. TZP should not be used for strains with an MIC of 8 mg/L or suspected OXA-1 co-production, irrespective of the infusion mode. IMPORTANCE Infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli represent a growing therapeutic challenge, particularly in critically ill patients. Carbapenems remain the reference treatment, but their overuse drives resistance emergence. Piperacillin-tazobactam is a potential carbapenem-sparing agent, but its clinical efficacy remains debated, partly due to the inoculum effect (a reduction in antibiotic activity at high bacterial densities) and suboptimal dosing regimens. Using a hollow-fiber infection model simulating the pharmacokinetics of critically ill patients, this study demonstrates that continuous infusion of piperacillin-tazobactam can overcome the inoculum effect under specific conditions, defined by the MIC of the infecting strain and the estimated bacterial density. These findings support a stratified approach to piperacillin-tazobactam use in severe ESBL-producing E. coli infections, based on MIC, inoculum size, and β-lactamase profile, and may help clinicians identify patients who could safely receive piperacillin-tazobactam instead of a carbapenem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliAnti-Bacterial Agentsbeta-LactamasesEscherichia coli InfectionsPiperacillin, Tazobactam Drug CombinationPenicillanic AcidMicrobial Sensitivity TestsHumansPiperacillin

Stichwörter der Autor:innen

ESBLEscherichia coligram-negative bacterial infectionshollow-fiber infection modelpharmacokineticsβ-lactam resistance

Substanzen

Anti-Bacterial Agentsbeta-LactamasesPiperacillin, Tazobactam Drug CombinationPiperacillinPenicillanic Acid

Autor:innen und Institutionen

  • Department of Medical Intensive Care, Univ Rouen Normandie, Univ de Caen Normandie, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Rouen, France.
  • Department of Anaesthesiology, Critical Care and Perioperative Medicine, Univ Rouen Normandie, Univ de Caen Normandie, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Rouen, France.
  • Department of Pharmacology, CHU de Rouen, Rouen, France.
  • Toxlab Laboratory, Paris, France.
  • Department of Infectious Diseases, Univ Rouen Normandie, Univ de Caen Normandie, INSERM, DYNAMICURE UMR 1311, CHU de Rouen, Rouen, France.
  • Normandie Univ, UNICAEN, UNIROUEN, INSERM, DYNAMICURE UMR 1311, Caen, France.

ORCID-Profile: Manuel Etienne, François Gravey, Kévin Alexandre

Zitieren

APA

Giry, M., Baulier, C., Lamoureux, F., Etienne, M., Nessi, N., Gravey, F., & Alexandre, K. (2026). Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.01457-26

Vancouver

Giry M, Baulier C, Lamoureux F, Etienne M, Nessi N, Gravey F, et al. Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.01457-26

BibTeX
@article{Giry2026,
  author = {Giry, Marion and Baulier, Charles and Lamoureux, Fabien and Etienne, Manuel and Nessi, Nicolas and Gravey, François and Alexandre, Kévin},
  title = {Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1128/spectrum.01457-26}
}
Kostenlos starten →